Monthly Archives: December 2019

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Synthorx, Inc. – (NasdaqGS: THOR)

BALA CYNWYD, PA / ACCESSWIRE / December 10, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synthorx, Inc. ("Synthorx" or "the Company") (NasdaqGS:THOR) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Sanofi (NASDAQ GS:SNY). Under the terms of the agreement, Synthorx shareholders will receive only $68.00 for each share of Synthorx common stock owned.

The investigation concerns whether the Synthorx Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Sanofi is underpaying for the Company. For example, the drug at the center of the deal is Synthorx's investigational medicine code-named THOR-707. Meant to treat solid tumors, the drug is designed to boost the number of cancer-fighting cells in the body, potentially overwhelming the disease with effector T-cells and natural killer cells.

If you own shares of Synthorx stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://www.brodskysmith.com/cases/synthorx-inc-nasdaqgs-thor/, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 569776

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Audentes Therapeutics, Inc. – (NasdaqGS: BOLD)

BALA CYNWYD, PA / ACCESSWIRE / December 10, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Audentes, Inc. ("Audentes" or "the Company") (NasdaqGS:BOLD) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Astellas Pharma, Inc. Under the terms of the agreement, Audentes shareholders will receive only $60.00 for each share of Audentes common stock owned.

The investigation concerns whether the Audentes Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Astellas is underpaying for the Company. The transaction may undervalue the Company. For example, the merger will provide Astellas with Audentes robust pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).

If you own shares of Audentes stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://www.brodskysmith.com/cases/audentes-therapeutics-inc-nasdaqgs-bold/, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 569775

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of The Medicines Company – (NasdaqGS: MDCO)

BALA CYNWYD, PA / ACCESSWIRE / December 10, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of The Medicines Company ("TMC" or "the Company") (NasdaqGS:MDCO) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Novartis AG. Under the terms of the agreement, TMC shareholders will receive only $85.00 for each share of TMC common stock owned.

The investigation concerns whether the TMC Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Novartis is underpaying for the Company. The transaction may undervalue the Company. For example, the acquisition, adds inclisiran, which had impressed in late-stage trials and is expected to seek US approval by the end of the year, to Novartis's R&D pipeline.

If you own shares of TMC stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://www.brodskysmith.com/cases/medicines-company-nasdaqgs-mdco/, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 569779

6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Domo, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 10, 2019 /  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Domo, Inc. ("Domo" or "the Company") (NASDAQ:DOMO) for violations of the federal securities laws.

Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO" or "Offering") commenced on or around June 29, 2018, or between June 28, 2018 and September 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before December 16, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Domo suffered weakness in its enterprise business as well as in international sales. The Company's growth of billings had slowed considerably. These issues were likely negatively impact the Company's financial results. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Domo, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 569806

HSI (OTC Pink: VRTY) is Leading the Paradigm Shift of Testing Patients With Opioid Alternatives for Pain Management

NEW YORK, NY / ACCESSWIRE / December 10, 2019 / Healthcare Solutions Holdings Inc. (OTC Pink:VRTY), a medical service and device company focused on providing clinicians with state-of-the-art diagnostic and therapeutic tools is leading the paradigm shift of treating patients with opioid alternatives for pain management.

Dr. Christina Robins

Cannabidiol, also known as CBD, has recently been covered in the media and the discussion of the medical benefits of CBD is underway. CBD is one of the many compounds in the cannabis plant and comes in an oil form, and doctors have found CBD to have major medical benefits. CBD may benefit a person's health in a variety of ways, treating diagnoses such as pain relief and inflammation, epilepsy, neurological symptoms and disorders, and anxiety just to name a few. A person can use CBD oil in different ways to relieve various symptoms since CBD-based products comes in many forms. CBD oil can be mixed into foods or drinks, swallowed in a pill form, or applied directly to the skin as a lotion. CBD is a healthy and clean option to treat many different health disorders, and it can replace many prescription drugs that may have major side effects. Dr. Christina Robins weighs in on the topic of using CBD medicinally below.

"Using CBD medicinally is a very new, yet interesting approach," says Dr. Robins. "CBD works in the cannabinoid system of our body and the CBD oil, created from the flower of a cannabis plant which creates an oil product, works on the CB1 and CB2 receptors. It is an interesting product because it is a calming treatment, it is mild and non-sedating, and moreover non-addictive. I prescribe CBD for conditions such as pain, anxiety, and sleep insomnia. Depending on the patient's needs, I sometimes will add CBD to the patient's pharmaceutical prescriptions to see if it is a better alternative to some medications. The success of CBD depends on the patients' cannabinoid system and how their receptors react to the CBD. As of right now, CBD usage and sales are a state by state event, so while some states are approved medically and/or recreationally, soon federal regulation will step in and hopefully end up having a federal stance on it. The main thing you're seeing helpful is once you bring in THC, even if you combine it with CBD, as it is less agitating to someone and it is better for pain, nausea, and cancer. I foresee quite a bit of education that will need to be done to the consumer and to doctors so people can really understand the positive and helpful effects CBD has."

"The CBD market is a really interesting area we are focused on in 2020," said Travis Revelle, CEO of Healthcare Solutions Holding Inc. "We are just scratching the service on how this plant can be used in medicine. With regulations being relaxed across the country, we want to be on the forefront of bringing the best possible form of CBD to our physicians."

HSI is a medical service, and device company focused on providing clinicians with state-of-the-art diagnostic and therapeutic tools. Our mission is to improve patient outcomes by helping clinicians gain broader access to the most advanced technology in the healthcare industry. HSI does not only focus on assisting physicians with exceptional healthcare delivery, but also promoting compliance with the industry's best practices.

Healthcare Solutions, Inc., headquartered in Glen Cove, New York. Please visit www.hscorp.biz for additional information.

CONTACT:

Jonathan Loutzenhiser
SVP Healthcare Solutions
Email: IR@HScorp.Biz
Email: MR@HScorp.Biz
Phone: +1 (866) 668-2188

Source: Healthcare Solutions Holdings, Inc.

ReleaseID: 569791

STOCKHOLDER ALERT: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Acquisition

NEW YORK, NY / ACCESSWIRE / December 10, 2019 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

Instructure, Inc (INST) related to its sale to PIV Purchaser, LLC. Under the terms of the Merger, each share of Instructure common stock will automatically be converted into the right to receive $47.60 in cash for each share of Instructure common stock owned. Click here for more information: https://www.monteverdelaw.com/case/instructure-inc. It is free and there is no cost or obligation to you.
Audentes Therapeutics, Inc (BOLD) related to its sale to Astellas Pharma, Inc. Under the terms of the Agreement, Audentes shareholders will have the right to receive $60.00 in cash for each Audentes common stock owned. Click here for more information: https://www.monteverdelaw.com/case/audentes-therapeutics-inc. It is free and there is no cost or obligation to you.
TD Ameritrade Holding Corporation (AMTD) ("Ameritrade") related to its sale to The Charles Schwab Corporation ("Schwab"). Under the terms of the Merger, Ameritrade common stock will be converted into the right to receive 1.0837 shares of Schwab voting common stock for each Ameritrade common stock owned. Click here for more information: https://www.monteverdelaw.com/case/td-ameritrade-holding-corporation. It is free and there is no cost or obligation to you.

Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019 an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

CONTACT:

Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2019 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE: Monteverde & Associates PC

ReleaseID: 569793

Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

EDISON, NJ / ACCESSWIRE / December 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the successful advancement to the next higher dose in its ongoing clinical trial of CRV431, a Phase 1 multiple ascending dose ("MAD") study.

The open-label MAD study was initiated in the third quarter of 2019 to assess safety, tolerability and pharmacokinetics of CRV431 in healthy volunteers. The study is designed to examine doses of 75 mg, 150 mg, 225 mg and 300 mg, with the potential to assess higher doses, where CRV431 is administered orally, once daily for 28 days.

Data are reviewed by a Clinical Trial Management team between each successive increase in dosing levels. The team's review of the 75 mg cohort data showed this dosing level to be safe and well tolerated, which authorized escalation to the next dosing level of 150 mg daily for 28 days. In addition to studying the safety, tolerability, and exposure after dosing of CRV431, the maximum tolerated dose in humans will be determined.

"As we proceed to the next dosing level, we will continue to monitor blood concentrations of CRV431, and all markers of safety," said Dr. Stephen Harrison, Hepion's Consultant Medical Director. "The data generated from this trial is expected to guide further development of CRV431 for the treatment of NASH, with plans to initiate Phase 2 clinical studies in the first half of 2020."

About Hepion Pharmaceuticals

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431's potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend," among others. These forward-looking statements are based on Hepion Pharmaceuticals' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2018 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

SOURCE: Hepion Pharmaceuticals, Inc.

ReleaseID: 569787

Zedge Announces First Quarter Fiscal 2020 Results

Paid Subscribers increase 74% from Q4 to 225 thousand through the end of November, generating gross revenue of $1 million since January 2019 launch

NEW YORK, NY AND TRONDHEIM, NORWAY / ACCESSWIRE / December 10, 2019 / Zedge, Inc. (NYSE AMERICAN:ZDGE) today announced results for the first quarter of its fiscal year 2020, the three months ended October 31, 2019.

First Quarter FY 2020 Operational and Financial Highlights

(Results are for the 1st quarter of FY 2020 and are compared to the 1st quarter of FY 2019 except where otherwise noted.)

MAU (Monthly Active Users) for the last 30 days of the quarter decreased 14.2% to 29.7 million from 34.6 million in the comparable period of 2019 primarily as a result of buggy code in a standard technology integration with one of our third-party advertising partners resulting in Google Play temporarily suspending our app from their store in late September and recommending that users uninstall the app; MAU declined 28.4% and 4.6% in well-developed markets and emerging markets respectively;
Total installs at October 31, 2019 increased 16.4% to 409 million from 351.3 million;
Revenue decreased 14.6% to $2.03 million from $2.38 million;
Paid subscribers increased 53% sequentially to 198 thousand;
Average revenue per MAU derived from our apps (ARPMAU) was flat at $0.0210;
Selling, General and Administration (SG&A) expense decreased 15.8% to $1.94 million from $2.31 million in the year ago quarter and 8.9% from $2.14 million in the prior sequential quarter, primarily attributable to reductions in compensation costs, recruiting fees, legal expense and auditing fees offset by higher marketing costs associated with the approximately 30% fee we pay to Google for each paid subscriber, severance payments and content acquisition expense associated with ‘Shortz';
Loss from operations during the quarter was $745 thousand, compared to a loss of $581 thousand a year ago and $939 thousand last quarter, after accounting for depreciation and amortization of $505 thousand in current quarter, $303 thousand in a year ago quarter and $405 thousand last quarter;
Zedge Premium GTV, or gross transaction value – that is the total sales volume transacting through the platform – increased to $192 thousand from $41 thousand a year ago and $167 thousand last quarter;
For the quarter, cash flow provided by operating activities was $352 thousand – a decline of $569 thousand compared to the same period last year but an improvement of $747 thousand when compared to last quarter;
Net loss per share of $0.08 compared to net loss per share of $0.07;
We launched ‘Shortz' a new entertainment app offering serialized, short-form fiction delivered in a text-message format in the United States, the United Kingdom and Canada in late November; and
On November 7, 2019 Elliot Gibber was appointed as interim-CEO after resigning from the Board of Directors.

Management Remarks

"Although we still have a lot of work ahead of us, I'm pleased that we are making tangible progress in our goal to become cashflow positive while simultaneously rolling out new and innovative products that extend our relevance beyond mobile phone personalization," said Elliot Gibber, Interim CEO. "In late November, we started rolling out Shortz, our new entertainment app offering serialized, short-form fiction delivered in a text-message format on Android, in the US, the UK, Australia and Canada. This is encouraging especially in light of adopting a paid subscription business model for this product. Our flagship app experienced another solid quarter of growth in our subscription-based "ad free" offering. By the end of November, we had more than 225 thousand paying subscribers generating approximately $1.0 million in gross revenue. We continue to see rapid adoption of paid subscriptions and we are testing mechanisms to further optimize and expand this offering."

Jonathan Reich, CFO and COO of Zedge, added, "Although revenues declined by 14.6% when compared to the year ago quarter, they increased 4.3% when compared to the sequential quarter, even in light of the Google temporary suspension. As discussed last quarter, we are highly focused on lowering costs while planning for growth. After backing out one-time expenses for all periods, SG&A would have been $1.87 million, a 19.2% and 11.2% decline when compared to the year ago quarter and sequential quarter, respectively. This spending cut happened in tandem with spending on the release of Shortz, a new and innovative product offering, growing paid subscriptions, and undertaking a host of new projects to drive more revenue from our business. The ongoing challenge with our flagship business relates to the continued shift in users from well developed markets to emerging markets. We will continue to leverage our massive user base to drive growth to our new initiatives, like our recently launched Shortz app. We recently overhauled our website to better position Zedge in top search results for ringtones or wallpapers. We expect this will drive more installs and increase the use of our app – both important growth drivers."

Financial Results by Quarter (USD in thousands, other than Loss per Share and ARPMAU)

 

 
Q1 FY '20
 
 
Q1 FY '19
 
 
Delta
 
 
% Change
 
 
Q1 FY '20
 
 
Q4 FY '19
 
 
Delta
 
 
% Change
 

Revenues

 
$
2,033
 
 
$
2,381
 
 
$
(348
)
 
 
-14.6
%
 
$
2,033
 
 
$
1,950
 
 
$
83
 
 
 
4.3
%

Direct Cost Of Revenue

 
$
328
 
 
$
350
 
 
$
(22
)
 
 
-6.3
%
 
$
328
 
 
$
348
 
 
$
(20
)
 
 
-5.7
%

Total SG&A

 
$
1,945
 
 
$
2,309
 
 
$
(364
)
 
 
-15.8
%
 
$
1,945
 
 
$
2,136
 
 
$
(191
)
 
 
-8.9
%

Depreciation & Amortization

 
$
505
 
 
$
303
 
 
$
202
 
 
 
66.7
%
 
$
505
 
 
$
405
 
 
$
100
 
 
 
24.7
%

Loss From Operations

 
$
(745
)
 
$
(581
)
 
$
(164
)
 
 
28.2
%
 
$
(745
)
 
$
(939
)
 
$
194
 
 
 
-20.7
%

Net Loss From FX & Other

 
$
(56
)
 
$
(122
)
 
$
66
 
 
 
-54.1
%
 
$
(56
)
 
$
(253
)
 
$
197
 
 
 
-77.9
%

Provision For Income Taxes

 
$
0
 
 
$
3
 
 
$
(3
)
 
 
-100.0
%
 
$
0
 
 
$
10
 
 
$
(10
)
 
 
-100.0
%

Net Loss

 
$
(801
)
 
$
(706
)
 
$
(95
)
 
 
13.5
%
 
$
(801
)
 
$
(1,202
)
 
$
401
 
 
 
-33.4
%

Diluted Loss Per Share

 
$
(0.08
)
 
$
(0.07
)
 
$
(0.01
)
 
 
11.6
%
 
$
(0.08
)
 
$
(0.12
)
 
$
0.04
 
 
 
-34.5
%

Total Current Assets Less Total Current Liabilities

 
$
484
 
 
$
3,045
 
 
$
(2,561
)
 
 
-84.1
%
 
$
484
 
 
$
1,178
 
 
$
(694
)
 
 
-58.9
%

MAU (Million)

 
 
29.7
 
 
 
34.6
 
 
 
(4.9
)
 
 
-14.2
%
 
 
29.7
 
 
 
33.8
 
 
 
(4.1
)
 
 
-12.1
%

Total Installs (Million)

 
 
409.0
 
 
 
351.3
 
 
 
57.7
 
 
 
16.4
%
 
 
409.0
 
 
 
395.9
 
 
 
13.1
 
 
 
3.3
%

ARPMAU

 
$
0.0210
 
 
$
0.0211
 
 
$
(0.000
)
 
 
-0.5
%
 
$
0.0210
 
 
$
0.0189
 
 
$
0.002
 
 
 
11.0
%

nm-not meaningful

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Earnings Announcement and Supplemental Information

Zedge's management will host an earnings conference call beginning at 4:30PM Eastern. Management's presentation of the results, outlook and strategy will be followed by Q&A with investors.

To participate in the call, please dial Toll Free: 844-602-0380 or International: 862-298-0970 at least five minutes before the 4:30PM Eastern start and ask for the Zedge earnings conference call.

The call will also be webcast through this URL:

https://www.investornetwork.com/event/presentation/56771 (through 3/10/20)

Following the call and continuing through 12/24/19, a call replay will be available by dialing Toll Free: 877-481-4010 or International: 919-882-2331 and entering the replay access code: 56771

Forward Looking Statements

All statements above that are not purely about historical facts, including, but not limited to, those in which we use the words "believe," "anticipate," "expect," "plan," "intend," "estimate," "target" and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors. Our filings with the SEC provide detailed information on such statements and risks, and should be consulted along with this release. To the extent permitted under applicable law, we assume no obligation to update any forward-looking statements.

About Zedge

Zedge offers a state-of-the-art digital publishing platform that powers our consumer-facing app availing users with a host of digital content – wallpapers, video wallpapers, ringtones, and stickers. We are evolving by developing new apps run on top of our publishing platform and generally focus on the entertainment vertical. Our creators are amateur and professional artists as well as new and major brands who can easily launch a virtual storefront in Zedge where they can market and sell their content to our user base. Our app has been downloaded more than 409 million times, has more than 29 million monthly active users and has consistently ranked as one of the most popular free apps in Google Play store in the United States.

CONTACT:

Jonathan Reich
ir@zedge.net

ZEDGE, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except par value data)
(Unaudited)

 

 
October 31,
 
 
July 31,
 

 

 
2019
 
 
2019
 

 

 
 
 
 
 
 

Assets

 
 
 
 
 
 

Current assets:

 
 
 
 
 
 

Cash and cash equivalents

 
$
1,659
 
 
$
1,609
 

Trade accounts receivable, net of allowance for doubtful accounts of $0 at October 31, 2019 and July 31, 2019

 
 
1,065
 
 
 
1,133
 

Prepaid expenses

 
 
220
 
 
 
380
 

Other current assets

 
 
57
 
 
 
103
 

Total current assets

 
 
3,001
 
 
 
3,225
 

Property and equipment, net

 
 
3,099
 
 
 
3,396
 

Goodwill

 
 
2,168
 
 
 
2,266
 

Other assets

 
 
583
 
 
 
120
 

Total assets

 
$
8,851
 
 
$
9,007
 

Liabilities and stockholders' equity

 
 
 
 
 
 
 
 

Current liabilities:

 
 
 
 
 
 
 
 

Trade accounts payable

 
$
328
 
 
$
217
 

Insurance premium loan payable

 
 
110
 
 
 
141
 

Accrued expenses and other current liabilities

 
 
1,466
 
 
 
1,172
 

Deferred revenues

 
 
613
 
 
 
517
 

Total current liabilities

 
 
2,517
 
 
 
2,047
 

Other liabilities

 
 
242
 
 
 

 

Total liabilities

 
 
2,759
 
 
 
2,047
 

Commitments and contingencies (Notes 8 and 12)

 
 
 
 
 
 
 
 

Stockholder' equity:

 
 
 
 
 
 
 
 

Preferred stock, $.01 par value; authorized shares-2,400; no shares issued

 
 

 
 
 

 

Class A common stock, $.01 par value; authorized shares-2,600; 525 shares issued and outstanding at October 31, 2019 and July 31, 2019

 
 
5
 
 
 
5
 

Class B common stock, $.01 par value; authorized shares-40,000; 9,876 shares issued, and 9,840 shares outstanding at October 31, 2019 and 9,876 shares issued and 9,854 ouststanding at July 31, 2019

 
 
99
 
 
 
99
 

Additional paid-in capital

 
 
23,229
 
 
 
23,131
 

Accumulated other comprehensive loss

 
 
(1,128
)
 
 
(985
)

Accumulated deficit

 
 
(16,044
)
 
 
(15,243
)

Treasury stock, 36 shares at October 31, 2019 and 22 shares at July 31, 2019, at cost

 
 
(69
)
 
 
(47
)

Total stockholders' equity

 
 
6,092
 
 
 
6,960
 

Total liabilities and stockholders' equity

 
$
8,851
 
 
$
9,007
 

ZEDGE, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands, except per share data)
(Unaudited)

 

 
Three Months Ended
 

 

 
October 31,
 

 

 
2019
 
 
2018
 

 

 
 
 
 
 
 

 

 
 
 
 
 
 

Revenues

 
$
2,033
 
 
$
2,381
 

Costs and expenses:

 
 
 
 
 
 
 
 

Direct cost of revenues (exclusive of amortization of capitalized software and technology development costs included below)

 
 
328
 
 
 
350
 

Selling, general and administrative

 
 
1,945
 
 
 
2,309
 

Depreciation and amortization

 
 
505
 
 
 
303
 

 

 
 
 
 
 
 
 
 

Loss from operations

 
 
(745
)
 
 
(581
)

Interest and other income

 
 

 
 
 
7
 

Net loss resulting from foreign exchange transactions

 
 
(56
)
 
 
(129
)

Loss before income taxes

 
 
(801
)
 
 
(703
)

Provision for income taxes

 
 

 
 
 
3
 

Net loss

 
 
(801
)
 
 
(706
)

Other comprehensive loss:

 
 
 
 
 
 
 
 

Changes in foreign currency translation adjustment

 
 
(143
)
 
 
(131
)

Total other comprehensive loss

 
 
(143
)
 
 
(131
)

Total comprehensive loss

 
$
(944
)
 
$
(837
)

Loss per share attributable to Zedge, Inc. common stockholders:

 
 
 
 
 
 
 
 

Basic and diluted

 
$
(0.08
)
 
$
(0.07
)

Weighted-average number of shares used in calculation of loss per share:

 
 
 
 
 
 
 
 

Basic and diluted

 
 
10,196
 
 
 
10,025
 

ZEDGE, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)

 

 
Three Months Ended
 

 

 
October 31,
 

 

 
2019
 
 
2018
 

 

 
 
 
 
 
 

 

 
 
 
 
 
 

Operating activities

 
 
 
 
 
 

Net loss

 

(801
)
 

(706
)

Adjustments to reconcile net loss to net cash provided by operating activities:

 
 
 
 
 
 
 
 

Depreciation and amortization

 
 
505
 
 
 
303
 

Stock-based compensation

 
 
98
 
 
 
121
 

Change in assets and liabilities:

 
 
 
 
 
 
 
 

Trade accounts receivable

 
 
68
 
 
 
541
 

Prepaid expenses and other current assets

 
 
207
 
 
 
238
 

Other assets

 
 
(13
)
 
 
3
 

Trade accounts payable and accrued expenses

 
 
192
 
 
 
408
 

Due to IDT Corporation

 
 

 
 
 
13
 

Deferred revenue

 
 
96
 
 
 

 

Net cash provided by operating activities

 
 
352
 
 
 
921
 

Investing activities

 
 
 
 
 
 
 
 

Capitalized software and technology development costs and purchase of equipment

 
 
(213
)
 
 
(445
)

Investment in privately-held company

 
 

 
 
 
(250
)

Net cash used in investing activities

 
 
(213
)
 
 
(695
)

Financing activities

 
 
 
 
 
 
 
 

Repayment of insurance premium loan payable

 
 
(31
)
 
 

 

Purchase of treasury stock in connection with restricted stock vesting

 
 
(22
)
 
 
(31
)

Net cash used in financing activities

 
 
(53
)
 
 
(31
)

Effect of exchange rate changes on cash and cash equivalents

 
 
(36
)
 
 
(42
)

Net increase in cash and cash equivalents

 
 
50
 
 
 
153
 

Cash and cash equivalents at beginning of period

 
 
1,609
 
 
 
3,408
 

Cash and cash equivalents at end of period

 

1,659
 
 

3,561
 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

 
 
 
 
 
 

Cash payments made for interest expenses

 

1
 
 


 

SOURCE: Zedge, Inc.

ReleaseID: 569744

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of QUAD, BAX and PLT

NEW YORK, NY / ACCESSWIRE / December 10, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Quad/Graphics, Inc. (NYSE:QUAD)
Class Period: February 21, 2018 to October 29, 2019
Lead Plaintiff Deadline: January 6, 2020

The QUAD lawsuit alleges that throughout the class period, Quad/Graphics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's book business in United States was underperforming; (2) as a result, the Company was likely to divest its book business; (3) the Company was unreasonably vulnerable to decreases in market prices; (4) to remain financially flexible while market prices decreased, the Company was likely to cut its quarterly dividend and expand its cost reduction programs; and (5) as a result of the foregoing, positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in QUAD: http://www.kleinstocklaw.com/pslra-1/quad-graphics-inc-loss-submission-form?id=4815&from=1

Baxter International Inc. (NYSE:BAX)
Class Period: February 21, 2019 to October 23, 2019
Lead Plaintiff Deadline: January 24, 2020

The BAX lawsuit alleges Baxter International Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) the Company lacked effective internal control over financial reporting; (3) as a result, the Company's financial statements were misstated and would likely require correction or amendment; (4) due to the Company's internal investigation, Baxter would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on Form 10-Q in a timely manner; and (5) as a result of the foregoing, Defendants' statements about the Company's business and operations lacked a reasonable basis.

Learn about your recoverable losses in BAX: http://www.kleinstocklaw.com/pslra-1/baxter-international-inc-loss-submission-form?id=4815&from=1

Plantronics, Inc. (NYSE:PLT)
Class Period: July 2, 2018 to November 5, 2019
Lead Plaintiff Deadline: January 13, 2020

The PLT lawsuit alleges that Plantronics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had engaged in channel stuffing to artificially boost sales; (2) the Company's internal control over inventory levels was not effective; (3) the Company had not adequately monitored inventory levels ahead of multiple product launches, where the new models would displace demand for aging products; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in PLT: http://www.kleinstocklaw.com/pslra-1/plantronics-inc-loss-submission-form?id=4815&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 569788

Hybrid Home Theaters Fit Nicely Into Newly Finished Basement Spaces

Popular multi-use family space includes multi-screen viewing, games, family time.

Warrenton, United States – December 10, 2019 /MarketersMedia/

Basement Solutions of Warrenton, VA, has been providing dry, finished basement spaces to homeowners who want to enjoy their whole home. There are many unfinished basement ideas which they can offer, but hybrid home theater promises to be a popular way to use these large, unused spaces.

The growing popularity of hybrid home theater spaces requires a significant square footage that many homes can’t spare until the basement space is considered. Proper construction and materials make an unused basement ready for the requirements of quality audio and video installations.

As trade publication CEPro notes, hybrid home theater puts viewing rooms to work as living spaces. With multiple screens, gaming systems, casual furniture and advanced sound systems, hybrid spaces are in use more of the time and bring the family together for engaging activities as well as movie watching.

Home theater installations generally require acoustic preparation of the walls and ceiling and management of outside light, which are both easy to accomplish when creating a finished basement. The basement waterproofing Virginia homes often need is the first step in creating many beautiful family spaces.

Unfinished basement dampness concerns can be addressed by Basement Solutions during the process of building a hybrid home theater. The right acoustic treatments will make the walls ready to support powerful, high-quality sound systems including architectural speaker systems in this formerly neglected space.

Homeowners who are interested in creating a hybrid home theater can contact Basement Solutions at 571-208-4048 for help in transforming their unfinished basements to an inviting entertainment space.

Contact Info:
Name: Scot Small
Email: Send Email
Organization: Basement Solutions
Phone: 571-208-4048
Website: http://www.solutions4basements.com/

Source URL: https://marketersmedia.com/hybrid-home-theaters-fit-nicely-into-newly-finished-basement-spaces/467519

Source: MarketersMedia

Release ID: 467519